A Supervised Exercise Intervention During Cancer Treatment for Adolescents and Young Adults - FiIGHTING F!T: Study Protocol of a Randomised Controlled Trial.

Claire Munsie (claire.munsie@health.wa.gov.au)
University of Western Australia
https://orcid.org/0000-0003-0268-9377

Jay Ebert
University of Western Australia

Joanne Collins
Sir Charles Gairdner Hospital

Megan Plaster
Sir Charles Gairdner Hospital

David Joske
Sir Charles Gairdner Hospital

Timothy Ackland
University of Western Australia

Study protocol

Keywords: Exercise, Treatment-Related Toxicity, Rehabilitation, Physical Activity.

Posted Date: March 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-59342/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

High quality evidence supports the integration of exercise to mitigate treatment-related side effects in a wide range of paediatric and adult cancer cohorts. However, the implementation of exercise in adolescent and young adult (AYA) cancer patients is yet to be explored in depth. FiGHTINGFIT is a randomised controlled cross over trial designed to determine if a supervised, structured and progressive exercise program can reduce the decline in physical fitness ($V_{O2peak}$) associated with cancer treatment in AYAs from diagnosis.

Methods/Design

A total of 40 AYAs recently diagnosed and due to commence systemic treatment ($\pm$ 2 weeks) for a primary haematological malignancy or solid tumour will be recruited and randomised to either an immediate exercise intervention or usual care (delayed exercise) for 10 weeks. This randomised controlled crossover trial will see both groups engage in a supervised exercise intervention from either diagnosis (baseline assessment) for 10 weeks (0-10 weeks) or following an interim assessment to 20 weeks (10-20 weeks). The bi-weekly tailored exercise program will combine aerobic and resistance exercises and be supervised by an Accredited Exercise Physiologist. Participants will complete a range of assessments at 0, 10 and 20 weeks including cardiopulmonary exercise tests, 1 repetition maximum strength measures, physical functioning and self-reported quality of life measurements. Patient reported treatment-related toxicities will be recorded on a weekly basis.

Discussion

The FiGHTINGFIT trial will provide insight into the potential benefits of a supervised exercise program in AYAs undergoing cancer treatment. This trial will contribute to the evidence supporting the necessary integration of exercise during cancer treatment, specifically in the under-reported AYA cohort.

Trial registration

This trial was registered retrospectively with the Australia New Zealand Clinical Trial registry (ACTRN12620000663954; https://www.anzctr.org.au/ACTRN12620000663954.aspx). Trial registry date: 10th June 2020.

Background

On average in Australia, two to three adolescents and young adults (AYAs) aged 15 to 25 years face the news of a cancer diagnosis each day.\(^{(1)}\) Between 2010–2014, 4,843 AYAs were diagnosed with cancer, reported as the leading cause of non-accidental death in this age range.\(^{(1–3)}\) While dispute persists internationally regarding the definition of AYAs by age in the cancer context, with ages ranging from 13–
39 years\(^{4–7}\) it is widely accepted that this cohort is biologically, physically and psychosocially unique.\(^{5}\) Adolescence is a period of transition characterised by significant developmental changes and, as such, a cancer diagnosis at this time can result in unique physical, psychosocial, educational, medical and vocational consequences for the young person which can last well into survivorship.\(^{4}\) Advances in cancer treatment have led to a rise in overall survival rates for combined AYA cancer diagnoses from 80–89% over the last three decades.\(^{1}\) Despite the obvious benefit borne by these improved survival rates, it also means that a larger proportion of AYA cancer survivors are living for decades with potentially devastating secondary physical and psychosocial consequences of their treatment.\(^{8, 9}\)

AYAs often undergo rigorous treatment protocols resulting in a plethora of physical and psychosocial side effects which can hinder their ability to complete activities of daily living (ADLs). Fatigue, pain, nausea, lack of appetite, vomiting, diarrhoea, loss of strength, impacts on executive function and peripheral neuropathy are commonly cited by AYAs, affecting their ability to function normally.\(^{10}\) If unresolved or poorly managed, these side effects can contribute to malnutrition, chronic fatigue, cancer-related cachexia and poor physical function, which perpetuates the cycle of inactivity and further deconditioning leading to poor physical functioning and outcomes.\(^{11}\) Further, this deconditioning can have detrimental effects on AYAs’ engagement in social, vocational and educational goals during and after cancer treatment.\(^{12, 13}\)

Over the last three decades, evidence supporting the integration of exercise in cancer cohorts has grown exponentially.\(^{14–16}\) It is now accepted that appropriately tailored exercise is safe and tolerable in a wide range of cancer cohorts, with national and international bodies calling for exercise to be embedded into standard cancer care.\(^{15, 17, 18}\) There is strong evidence that exercise mitigates the known effects of cancer treatments including cancer-related fatigue, muscle wasting, cardiorespiratory decline and psychological distress.\(^{19–21}\) However, this research is primarily in adult and paediatric cohorts, with a paucity of high-quality evidence available in AYA specific populations.\(^{22}\) Several small, single centre, non-randomised studies and reviews have demonstrated some benefits on the prevention of functional decline, reduction in fatigue and on quality of life variables in AYAs.\(^{23–26}\) However, while these results are promising, it is recognised that they need to be further explored in a high quality, randomised controlled trial.\(^{22}\)

In order to address the distinct lack of understanding of integrated exercise on functional capacity and treatment toxicity management in AYAs during cancer treatment, we developed this randomised controlled trial. The primary aim of the study is to determine whether a 10-week individualised exercise intervention is associated with a reduction in the decline of physical fitness (\(V_{\text{O}_2}\text{peak}\)) experienced by AYAs during cancer treatment, when compared with controls. Secondary aims are to assess the effects of the intervention on muscular strength, body composition, functional capacity, treatment-related toxicities and psychosocial variables. The purpose of this paper is to detail the FiGHTINGF!T study design and protocol based on the Standard Protocol Items for Randomised Trials (SPIRIT) guidelines.
Methods

Study design

The FiGHTINGFIT trial is a prospective, single centre, randomised controlled (RCT) cross over trial. Following baseline assessments, participants will be randomised to either immediate exercise or delayed exercise (usual care) for an initial period of 10 weeks. Following an interim assessment at 10 weeks, participants will cross over to the opposing group and either commence exercise (delayed exercise group) or commence usual care. There will be no wash out period between groups. The study is registered at the Australia New Zealand Clinical Trial Registry (ANZCTR) (ACTRN12620000663954) with participant recruitment for the trial now initiated. Proposed study activities are outlined as per SPIRIT guidelines (Table 1; Additional file 2). The RCT will be conducted over three years at the Sir Charles Gairdner Hospital, Perth, Australia. Figure 1. depicts the study design as per the CONSORT guidelines for randomised crossover trials.\(^{(27)}\)

Table 1. Proposed study activities and summary of assessments
Study population

Participants will be recruited through direct referral to the Western Australian Youth Cancer Service (WAYCS) from treating oncology and haematology clinicians based in Perth Metropolitan hospitals. Participants will be deemed eligible if they meet the following criteria:

1. Aged between 15 and 25 years of age as per the Australian definition of AYAs in cancer care.
2. Diagnosed with a primary haematological malignancy or solid tumour.
3. Scheduled to commence systemic cancer treatment (e.g. chemotherapy, radiation therapy or a combination of both within a +/- 2 week period).
4. Medically stable as determined by their treating medical practitioner.

Participants will be deemed ineligible to participate if they: (1) undergo surgery only, (2) have < 6 months life expectancy, (3) have insufficient English competency or a cognitive impairment that would prevent...
them from participating in the exercise assessments or programs, (4) are pregnant or lactating and/or (5) have any absolute contraindications to exercise and are deemed inappropriate by their medical treating team.

**Recruitment**

This trial will be conducted at Sir Charles Gairdner Hospital. The trial has been approved by the Human Research Ethics Committee and Research Governance Committee at the site (RGS00714) and at the University of Western Australia. All patients who meet the eligibility criteria will be approached within 2 weeks of being diagnosed and will be invited to participate in the study. Potential participants will receive detailed written and verbal information regarding implications of participation, risks and benefits, and alternatives to participation. Potential participants will have the opportunity to discuss the study with their treating clinicians and any WAYCS staff prior to undertaking the formal consent process. Those participants who are deemed eligible and agree to participate will be asked to provide written informed consent for study participation. For those participants under 18 years of age, the consent process will be undertaken with their parent/guardian in attendance and consent will be sort from both the participant and their parent/guardian. Additionally, written medical clearance will be sought from their treating oncologist or haematologist, without which the participant will be deemed ineligible to participate.

**Randomisation and blinding**

As this is not a homogenous group, prior to randomisation, participants will be stratified according to intensity of their cancer treatment regimen; high intensity versus low/moderate intensity treatment. Table 2. demonstrates stratification of the most common cancers diagnosed in the AYA age range. Any participant recruited with a diagnosis not listed in Table 2. will be discussed within the research team and treating clinicians to determine the intensity of their treatment regimen. The division between low/moderate versus high intensity relates to the likelihood of low blood counts and degree of immunosuppression from the treatment regimen.

| Low/Moderate intensity treatment diagnoses | High intensity treatment diagnoses |
|------------------------------------------|---------------------------------|
| Hodgkin lymphoma                         | Acute lymphoblastic leukaemia   |
| Germ cell tumours                        | Lymphoblastic lymphoma          |
| Gynaecological tumours                   | Burkitt lymphoma                |
| Non-Hodgkin lymphoma (excluding Burkitt) | Soft tissue and bone sarcoma    |
| Melanoma                                 | Squamous cell carcinoma of the head and neck |

Following stratification, participants will be randomised via a computer-generated block randomisation (sealed envelope) procedure. Both high and moderate intensity treatment groups will be randomised in block sizes of 4 and 8 into the two intervention groups: immediate exercise or usual care (delayed
exercise) intervention. The block randomisation will allow for equal groups to be created by the end of the recruitment. Given the nature of the intervention it is not possible to blind the investigators or the participants to their group allocation. However, the study personnel responsible for conducting primary outcome assessments will be blinded to participant group allocation.

Intervention

All participants will complete baseline assessments and be randomised prior to commencing (± 2 weeks) systemic treatment. All exercise programs will be individually prescribed by an Accredited Exercise Physiologist (AEP) and tailored relative to each patient’s presentation. The programs will follow the American College of Sports Medicine (ACSM) and Exercise and Sports Science Australia (ESSA) guidelines for combined aerobic and resistance exercise for cancer patients.\(^{16, 21}\) All exercise sessions will be undertaken in a one-on-one basis within a purpose-built gymnasium in the hospital setting and will be supervised by an AEP. All participants will be asked to complete an activity journal to capture any incidental exercise they may perform throughout the course of the trial, and the contents of the journal will be checked on a weekly basis.

**Immediate exercise group**

These participants will commence their exercise program the week following their baseline assessment and will be required to attend two supervised exercise sessions per week for 10 weeks. Sessions will be approximately 60 minutes in duration and scheduled at appropriate times relative to participants’ treatment schedules, with exercise conducted prior to or > 24 hours following chemotherapy administration. Participants will complete a post-intervention assessment at 10 weeks. Following the 10-week interim assessment, participants will then receive no further structured supervised exercise intervention for the remaining 10 weeks, prior to the subsequent final assessment at 20 weeks.

**Delayed exercise intervention (usual care)**

These participants will not be offered any exercise intervention for the initial 10 weeks following baseline assessment. There will be no specific exercise prescription provided to the participants other than that contained in generic information provided by treating teams to all patients as part of the usual standard of care. Participants randomised to this treatment arm will also complete an interim assessment at 10 weeks. Following the interim assessment, participants will then commence bi-weekly supervised exercise sessions for 10 weeks reflecting that offered to the immediate exercise group. Participants will complete final assessments at 20 weeks.

**Exercise prescription**

All exercise sessions will be multi-modal and follow the same format throughout the 10-week intervention. Participants will commence each session with a five-minute warm up, followed by aerobic bouts, a resistance training component and concluding with a 5-minute cool down and static stretching period of major muscle groups. The aerobic component of the program will be based on the participant’s physical capabilities and preference of the modalities available within the gym (including cycling on an
upright/recumbent bike, treadmill walking/jogging and/or skipping) and aim to accumulate 20–30 minutes at moderate intensity over the duration of the session. Intensity will be monitored using heart rate (HR) and rating of perceived exertion (RPE). Moderate intensity aerobic exercise is considered 60–85% of maximal heart rate \((220\text{–age})\) or an RPE of 12–14. Participants who are unable to complete 20 minutes continuously will aim to accumulate the required load in bouts of 5 to 10 minutes as tolerated. The resistance training component will comprise of 6–8 exercises targeting the major muscle groups of the body. Participants will complete 2–4 sets of 8–15 repetitions, at 60–80% of 1 repetition maximum (1RM) or an RPE of 12–14. Based on the thorough baseline assessment, any pre-existing injuries or treatment-related effects will be considered when prescribing and progressing all exercises. The sessions will aim to increase in exercise intensity as tolerated. Participants will also be encouraged to engage in aerobic exercise outside of supervised exercise sessions and asked to document their activity in exercise journals to meet exercise recommendations for cancer survivors. Exercise programs will be modified on a weekly basis as required relative to participants’ treatment schedules and related side effects, as well as changes in their individual physical conditioning throughout the program. Participants’ vital signs and most recent full blood picture will be reviewed prior to commencing each and every exercise session, to determine their safety for exercise and any need for program modification.

Primary outcome measure

The primary outcome of this RCT is cardiorespiratory fitness \((V_{02}\text{peak})\) as measured by a submaximal cardiopulmonary exercise test (CPET). The submaximal test will be conducted in a research setting by trained exercise specialists only, who will be blinded to the participant group allocation. Participants will be instructed to follow their usual diet and incidental activity and abstain from formal exercise in the 24 hours prior to testing. Additionally, the study team will review participants’ recent blood test results prior to assessments to ensure results are within the safe parameters for exercise. Prior to commencing the test, participants’ resting heart rate and blood pressure will be measured and a heart rate monitor will be attached to the participant (Wahoo Tickr heart rate monitor, Wahoo Fitness LLC, Georgia, USA). Target heart rate (THR) will be calculated using the formula \((220\text{–age}) \times 0.85\) which will be used as criteria to terminate the test unless volitional exhaustion is met prior to this. Participants will be sat on a front access Exertech Ex-10 cycle ergometer (Repco Cycle Company, Huntingdale, Victoria, Australia) and familiarised with the testing protocol. The ramped protocol will have participants commence cycling at 20 watts(W) for 1 minute and continue to increase by 20W per minute until they reach their THR or volitional exhaustion. Participants will complete the stage in which they reach their THR unless concluded prior to this. At the end of each minute, heart rate and RPE will be recorded. Participants will complete a 3-minute cool down on the bike pedalling with no resistance at a self-selected slow speed. Recovery heart rate and blood pressure will be recorded 10 minutes after the cessation of the test. During the test, participants will be required to breathe through a mouthpiece connected to a computerised gas analysis system. The system includes a ventilometer (Universal ventilation meter, Vacumed, Ventura, CA, USA) and oxygen and gas analysers (Ametek Applied Electrochemistry S-3A/1 and
CD-3A, AEI Technologies, Pittsburgh, PA) which calculate minute ventilation ($V_{E}$), respiratory exchange ratios (RER) and oxygen and carbon dioxide in expired air at 15 second intervals respectively. Calibration of the equipment will be conducted prior to and following each test using a standard reference gas of known concentration. Values at the conclusion of the test will be recorded in absolute (L/Min) and relative (mL/kg/min) terms. Predicted peak oxygen consumption ($V_{O_{2peak}}$) will be extrapolated using the participants’ heart rate (HR) and $V_{O_{2}}$ from two submaximal stages from the test where a steady state heart rate between 115–150 beats per minute is recorded. The slope will be calculated using the ratio of difference between the two submaximal $V_{O_{2}}$ measures and their corresponding heart rates and then be used to extrapolate to predicted maximal heart rate (220- age).\(^{(32–35)}\)

Secondary outcome measures

Strength and physical function

Gross muscular strength will be assessed using a one-repetition maximum test for chest press, decline leg press and seated row, recorded in kilograms (kg). Participants with any known bone metastases will be excluded from completing tests that load the location of affected bone.\(^{(16)}\) Testing will be conducted by an AEP in accordance with standard ACSM guidelines.\(^{(29)}\) Bilateral grip strength will be assessed using a grip strength dynamometer (Jamar Plus Digital, Paterson Medical, IL, USA) with the best of three attempts recorded in kilograms. Functional upper limb and lower limb endurance will be assessed using 30-second push ups and sit ups and a 5-repeated sit to stand (STS) test.\(^{(29)}\)

Anthropometry, body composition and body mass index

Body mass (kg), height (cm), body mass index (BMI, $m^2$) and body surface area ($m^2$) will be recorded as anthropometric measures. Body mass will be measured to the nearest 0.1 kg on electronic scales (Sauter Model EB60, FSE Scientific, Sydney, Australia) with participants asked to remove their shoes and heavy clothing. Body surface area ($m^2$) will be obtained from the participants’ chemotherapy charts from within their medical records as it will be used to analyse chemotherapy-related toxicities. Height will be measured using a wall mounted stadiometer to the nearest 0.1 cm (Seca 216 Measuring Pole, Birmingham, UK) and BMI will be calculated using recorded body mass and height by dividing body mass (kg) by height in metres squared ($m^2$). Waist and hip circumference will be measured using standardised testing protocols.\(^{(34)}\) Dual-energy X-ray absorptiometry will be used to record total lean mass (kg) (LM), total fat mass (kg) (FM), proportion of total mass being body fat (%) (%FM) and bone mineral density (BMD) (DXA; Lunar Prodigy, GE Medical Systems, Madison, WI, USA).

Patient reported activity and quality of life (QoL)

Patient reported physical function, emotional and social wellbeing, fatigue and quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C30),\(^{(36)}\) the Hospital Anxiety and Depression Score (HADS)\(^{(37)}\) and an age-
specifc version of the PEDS-QL and Multidimensional fatigue scale questionnaires. (38–40) Each of the quality of life tools are commonly used and have been validated in AYAs. Participant self-reported physical activity will be assessed using the International Physical Activity Questionnaire. (41)

Patient reported treatment-related toxicities

In order to determine that participants meet the safety requirements to complete exercise sessions, they will be required to undergo weekly full blood count (FBC), urea and electrolyte (U&E) and liver function (LFT) blood tests. These results will be reviewed prior to each exercise session to ensure participants meet predetermined safety parameters for exercise. (30) The results will also be reviewed and graded as per the Common Terminology Criteria for Adverse Events (CTCAE Version 5.0) (42) to determine any impact exercise may have on these variables. Further, participants will be contacted weekly by a member of the research team blinded to group allocation to determine if the participant has experienced any additional treatment-related side effects, including but not limited to nausea, vomiting, constipation, pain and fatigue (Additional file 1). (42) These participant-reported side effects will also be graded by the research team as per the CTCAE version 5.0. (42)

Feasibility

The feasibility of the exercise intervention will be determined based on eligibility rate, recruitment rate, compliance to the study protocol, adherence to the exercise intervention and withdrawal rates. Safety will be assessed by monitoring for any adverse or serious adverse events during any of the assessments or supervised exercise sessions. Any adverse events will be reported to the appropriate HREC bodies within an expedient time frame. All data will be collected, input and stored in accordance with HREC guidelines as outlined in FiGHTINGFIT Protocol Version 2 03012019.

Statistical Consideration

A total of 40 participants will be recruited, evaluated and analysed as part of this study. Analysis will be performed using an intention to treat approach. (43) A power analysis using PS Power and sample size calculations Version 3.1.2 has been performed to calculate the sample size required for this study, based on the primary outcome variable VO$_2$peak (ml.kg.min$^{-1}$). In the absence of comparable published data in AYA patients, similar studies undertaken by Thorsteinsson et al. (44) and West et al. (45) in paediatric and adult patients demonstrated an effect size of 0.80. The standard deviation across multiple studies utilising VO$_2$peak as the primary outcome measure varies from 1.5 ml.kg.min$^{-1}$ to 5.7 ml.kg.min$^{-1}$ and, therefore, a median value (3.6 ml.kg.min$^{-1}$) has been utilised for this trials sample size calculation. Assuming a 5% significance level and a power of 0.8, a sample size of 36 patients (18 per group) will be required. An additional 10% has been included (n = 4) to allow for attrition or unusable data.

Standard descriptive statistics (M, SD, n,%) will be calculated to summarise data on participant demographics and recruitment rates. Outcome analyses will include Student’s t-test, chi-square,
correlation, regression and repeated measures ANOVA to examine differences over time. Further statistical analysis will be employed to investigate any associations between exercise related changes and TRTs. Any clinically relevant covariates will be included in the analyses. All statistical analyses will be conducted using SPSS software (version 20.0, IBM, Armonk, NY, USA) and significance will be set at $p \leq 0.05$.

**Dissemination**

The results for the primary and secondary outcomes of this RCT will be shared regardless of the direction or magnitude of the effect. These outcomes are planned to be published in international high-quality, peer reviewed journals. Results will also be presented at national and international conferences as well as used for teaching purposes to community and university led forums.

**Discussion**

To the best of our knowledge this will be the first RCT to examine the benefits of a structured, supervised exercise intervention in AYAs from their cancer diagnosis and throughout their subsequent treatment. Furthermore, it will be the first RCT to explore the potential impact that exercise has on patient-reported treatment-related toxicities. In addition, we will explore any relationship evident between changes in physical functioning and patient reported treatment-related toxicities.

The design of this study represents both a strength and potential weakness. While a control group is essential to be able to determine any impact that exercise has in the intervention group, the research team deems it unethical to actively encourage sedentary behaviour. In order to address this, the cross over design allows for both groups to be exposed to the exercise intervention and will determine the most appropriate timing for the intervention. Additionally, both groups will be asked to record any physical activity they complete throughout the trial which will be accounted for as potential covariate in the final analysis. Nonetheless, the crossover design will also permit an ability to evaluate any changes in exercise-related beliefs or practices in the immediate exercise group, following their initial 10-week exercise program.

If it is demonstrated that this exercise intervention prevents functional decline associated with cancer treatment in AYAs, then such programs can be adopted widely in this cohort. Further, this research will allow clinicians to better understand the potential benefits of exercise on mitigating treatment-related toxicities encouraging targeted research by toxicity, aiming to improve overall treatment tolerance in AYAs.

**Conclusion**

There is a paucity of randomised controlled trials investigating exercise interventions in AYA cancer cohorts. The FiGHTINGF!T trial will aim to address the obvious lack of evidence in this area and
ultimately provide insight into the potential benefits of exercise in this vulnerable and underreported population.

**Abbreviations**

1RM  
1 repetition maximum  
ACSM  
American College of Sports Medicine  
ADL  
Activity of daily living  
AEP  
Accredited Exercise Physiologist  
ANZCTR  
Australia New Zealand clinical trial registry.  
AYA  
Adolescent and young adult  
BMD  
Bone mineral density  
CPET  
Cardiopulmonary exercise tests  
CONSORT  
Consolidated standards of reporting trials  
CTCAE  
Common terminology criteria for adverse events  
ESSA  
Exercise and Sports Science Australia  
EORTC QLQ-C30  
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30  
FBC  
Full blood count  
FM  
Fat mass  
HADS  
Hospital anxiety depression score  
HR  
Heart rate  
HREC  
Human research ethics committee  
LFT
Liver function tests
LM
Lean mass
M
Mean
PEDS-QL
Paediatric quality of life inventory
QOL
Quality of Life
RCT
Randomised controlled trial
RPE
Rating of perceived exertion
SD
Standard deviation
SPIRIT
Standard Protocol Items:Recommendations for Interventional Trials
THR
Target heart rate
U&E
Urea and Electrolytes
VO\textsubscript{2peak}
Peak oxygen uptake
WAYCS
Western Australian Youth Cancer Service.
1. Welfare AloHa. Cancer in adolescents and young adults in Australia. Canberra AIHW; 2018.
2. Roder DM, Warr A, Patterson P, Allison KR. Australian adolescents and young adults trends in cancer incidence, mortality, and survival over three decades. Journal of adolescent and young adult oncology. 2018;7(3):326 – 38.
3. Health Alo, Welfare. Australian Burden of Disease Study impact and causes of illness and death in Australia 2011. Canberra:AIHW; 2016.

Declarations

Trial status

The FiGHTINGF!T study is currently recruiting. Recruitment commenced in December 2018 and expected to finalise in January 2021. This study is being conducted in accordance with FiGHTINGF!T Protocol Version 2 03012019.
Funding: The study was assisted by the Sony Foundation You Can Innovate Award and the Exercise and Sports Science Australia Clinical Exercise Physiology Research grant. Funders have had and will have no role in the study design, data collection, analysis and interpretation of data or submission for publication processes.

Ethics approval: This study was approved by the Human Research Ethics Committee (HREC) of the Sir Charles Gairdner and Osborne Park Hospital Group (SCGOPHG) and The University of Western Australia and performed in line with the principles of the Declaration of Helsinki (Protocol Version 2.03012019).

Consent to participate: Not applicable for study protocol. Written informed consent will be obtained for the prospective RCT to follow.

Consent for publication: As above.

Conflict of interest/Competing interests: The authors declare that they have no conflicts of interest.

Availability of data and material: Not applicable.

Code availability: Not applicable.

Peer review: Peer reviewed for ethical and funding approval prior to submission.

Author contributions: All authors contributed to the study conception and design. Data collection was performed by C.M. Preliminary data analysis was performed by C.M. Final data analysis was performed by M.P. The first draft of the manuscript was written by C.M with all authors contributing to the final review and approval of the final manuscript.

Acknowledgements

The authors acknowledge the staff of the Western Australian Youth Cancer Service (WAYCS) for support for this project. The study will be assisted by the Sony Foundation You Can Innovate Award and the Exercise and Sports Science Australia Clinical Exercise Physiology Research Grant.

References

1. Welfare AloHa. Cancer in adolescents and young adults in Australia. Canberra: AIHW; 2018.
2. Roder DM, Warr A, Patterson P, Allison KR. Australian adolescents and young adults: trends in cancer incidence, mortality, and survival over three decades. Journal of adolescent and young adult oncology. 2018;7(3):326-38.
3. Health Alo, Welfare. Australian Burden of Disease Study: impact and causes of illness and death in Australia 2011. Canberra: AIHW; 2016.
4. Australia C. National Service Delivery Framework for Adolescents and Young Adults with Cancer. 2008.
5. Barr RD, Ferrari A, Ries L, Whelan J, Bleyer WA. Cancer in adolescents and young adults: a narrative review of the current status and a view of the future. JAMA pediatrics. 2016;170(5):495-501.

6. Fern L, Whelan J. National Cancer Research Institute teenage and young adult clinical studies group: the United Kingdom approach to research. International perspectives on AYAO, part 4. Journal of adolescent and young adult oncology. 2013;2(4):161-6.

7. Fernandez C, Fraser GA, Freeman C, Grunfeld E, Gupta A, Mery LS, et al. Principles and recommendations for the provision of healthcare in Canada to adolescent and young adult–aged cancer patients and survivors. Journal of adolescent and young adult oncology. 2011;1(1):53-9.

8. Guy GP, Yabroff KR, Ekwueme DU, Smith AW, Dowling EC, Rechis R, et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health affairs (Project Hope). 2014;33(6):1024.

9. Sawyer S, McNeil R, Thompson K, Orme L, McCarthy M. Developmentally appropriate care for adolescents and young adults with cancer: how well is Australia doing? Supportive Care in Cancer. 2019;27(5):1783-92.

10. Zebrack B, Kent EE, Keegan TH, Kato I, Smith AW, 1 AHSCG. “Cancer sucks,” and other ponderings by adolescent and young adult cancer survivors. Journal of psychosocial oncology. 2014;32(1):1-15.

11. Lucía A, Earnest C, Pérez M. Cancer–related fatigue: can exercise physiology assist oncologists? Lancet Oncology. 2003;4(10):616-25.

12. Husson O, Prins JB, Kaal SE, Oerlemans S, Stevens WB, Zebrack B, et al. Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. Acta Oncologica. 2017;56(2):288-94.

13. Sodergren SC, Husson O, Robinson J, Rohde GE, Tomaszewska IM, Vivat B, et al. Systematic review of the health-related quality of life issues facing adolescents and young adults with cancer. Quality of Life Research. 2017;26(7):1659-72.

14. Cormie P, Trevaskis M, Thornton-Benko E, Zopf EM. Exercise medicine in cancer care. Australian Journal of General Practice. 2020;49(4):169-74.

15. Cormie P, Atkinson M, Buccy L, Cust A, Eakin E, Hayes S, et al. Clinical Oncology Society of Australia position statement on exercise in cancer care. The Medical Journal of Australia. 2018;209(6):1.

16. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Medicine & Science in Sports & Exercise. 2019;51(11):2375-90.

17. Schmitz KH, Campbell AM, Stuiver MM, Pinto BM, Schwartz AL, Morris GS, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA: a cancer journal for clinicians. 2019;69(6):468-84.

18. Campbell KL, Winters-Stone KM, Patel AV, Gerber LH, Matthews CE, May AM, et al. An Executive Summary of Reports From an International Multidisciplinary Roundtable on Exercise and Cancer: Evidence, Guidelines, and Implementation. Rehabilitation Oncology. 2019;37(4):144-52.
19. Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiologic reviews. 2017;39(1):71-92.

20. Kleckner IR, Dunne RF, Asare M, Cole C, Fleming F, Fung C, et al. Exercise for Toxicity Management in Cancer—A Narrative Review. Oncology & hematology review. 2018;14(1):28-37.

21. Hayes SC, Newton RU, Spence RR, Galvão DA. The Exercise and Sports Science Australia position statement: Exercise medicine in cancer management. Journal of science and medicine in sport. 2019.

22. Munsie C, Ebert J, Joske D, Ackland T. The benefit of physical activity in adolescent and young adult cancer patients during and after treatment: a systematic review. Journal of adolescent and young adult oncology. 2019;8(5):512-24.

23. Murnane A, Thompson K, Mancuso SG, Lewin J, Orme LM. Exploring the effect of exercise physiology intervention among adolescent and young adults diagnosed with cancer. Rehabilitation Oncology. 2019;37(2):55-63.

24. Rosipal NC, Mingle L, Smith J, Morris GS. Assessment of voluntary exercise behavior and active video gaming among adolescent and young adult patients during hematopoietic stem cell transplantation. Journal of Pediatric Oncology Nursing. 2013;30(1):24-33.

25. Wu W-W, Jou S-T, Liang S-Y, Tsai S-Y. The Mediating Role of Exercise on Relationships Between Fatigue, Sleep Quality, and Quality of Life for Adolescents With Cancer. Cancer Nursing. 2019;42(2):E10-E9.

26. Zhi X, Xie M, Zeng Y, Liu J-e, Cheng AS. Effects of Exercise Intervention on Quality of Life in Adolescent and Young Adult Cancer Patients and Survivors: A Meta-Analysis. Integrative Cancer Therapies. 2019;18:1534735419895590.

27. Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378.

28. Borg GA. Psychophysical bases of perceived exertion. Medicine & Science in Sports & Exercise. 1982.

29. Medicine ACoS. ACSM’s guidelines for exercise testing and prescription: Lippincott Williams & Wilkins; 2013.

30. Maltser S, Cristian A, Silver JK, Morris GS, Stout NL. A focused review of safety considerations in cancer rehabilitation. PM&R. 2017;9(9):S415-S28.

31. Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. The lancet oncology. 2008;9(8):757-65.

32. Fox 3rd S, Haskell W. Physical activity and the prevention of coronary heart disease. Bulletin of the New York Academy of Medicine. 1968;44(8):950.

33. Glass S, Dwyer GB, Medicine ACoS. ACSM’S metabolic calculations handbook: Lippincott Williams & Wilkins; 2007.

34. Medicine ACoS. ACSM’s exercise testing and prescription: Lippincott williams & wilkins; 2017.
35. Morielli AR, Usmani N, Boulé NG, Tankel K, Severin D, Nijjar T, et al., editors. A phase I study examining the feasibility and safety of an aerobic exercise intervention in patients with rectal cancer during and after neoadjuvant chemoradiotherapy. Oncology nursing forum; 2016: Oncology Nursing Society.

36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute. 1993;85(5):365-76.

37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatræa scandinavica. 1983;67(6):361-70.

38. Varni J, Limbers C. The PedsQL™ Multidimensional Fatigue Scale in young adults: feasibility, reliability and validity in a University student population. Quality of Life Research. 2008;17(1):105-14.

39. Varni JW, Limbers CA. The PedsQL™ 4.0 generic core scales young adult version: feasibility, reliability and validity in a university student population. Journal of health psychology. 2009;14(4):611-22.

40. Ewing JE, King MT, Smith NF. Validation of modified forms of the PedsQL generic core scales and cancer module scales for adolescents and young adults (AYA) with cancer or a blood disorder. Quality of Life Research. 2009;18(2):231-44.

41. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Medicine & science in sports & exercise. 2003;35(8):1381-95.

42. Health NIo. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v. 5, November 2017. 2019.

43. Gupta SK. Intention-to-treat concept: a review. Perspectives in clinical research. 2011;2(3):109.

44. Thorsteinsson T, Larsen HB, Schmiegelow K, Thing LF, Krstrup P, Pedersen MT, et al. Cardiorespiratory fitness and physical function in children with cancer from diagnosis throughout treatment. BMJ Open Sport Exerc Med. 2017;3(1):e000179.

45. West M, Loughney L, Lythgoe D, Barben C, Sripadam R, Kemp G, et al. Effect of prehabilitation on objectively measured physical fitness after neoadjuvant treatment in preoperative rectal cancer patients: a blinded interventional pilot study. British journal of anaesthesia. 2015;114(2):244-51.

Figures
Figure 1

Schematic overview of the FiGHTINGF!T trial.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• Additionalfile1.FiGHTINGFTWeeklytoxicymonitoring.pdf
• Additionalfile2.SPIRITChecklist.doc
• FIGHTINGFTPICF13082019.docx